End-to-end translational pipelines from high-throughput phytochemical identification to multi-center clinical evaluations, manufactured under strict international cGMP quality systems.
The transformation of natural medicine manufacturing from empirical isolation to computational phytochemical biology, continuous flow technology, and standardized multi-target drug validation.
Unlike single-target chemical synthetics, botanical medicines and dietary supplements interact across network biology pathways. Modern contract development mandates metabolomic fingerprinting, identifying the interconnected role of glycosides, flavonoids, polysaccharides, and terpenoids to formulate therapies that resist target mutational escape.
Global pharmaceutical corporations increasingly outsource raw botanical processing to specialized contract manufacturers located within natural origin ecosystems. Sourcing integrity relies on eliminating batch variations driven by climate instability, seasonal deviations, soil heavy metals, and pesticide residuals using automated molecular grading.
The regulatory convergence between dietary supplements, traditional herbal medicinal products (THMP), and prescription botanical drugs demands clinical rigor. Leading pharmaceutical enterprises require contract suppliers capable of generating comprehensive dossiers from GLP toxicity assays to Phase IV post-market efficacy surveillance.
Directly addressing the critical friction points in global contract manufacturing: reproducibility, patent sovereignty, yield loss, and technical transfer delays.
Under our strict contract manufacturing model, customer proprietary formulas, fraction fractionation maps, and manufacturing blueprints are ring-fenced under non-disclosure protocols. Data rooms, physical air-gapped pilot runs, and exclusive supply contracts ensure total IP sovereignty for innovators.
Bridging the notorious "valley of death" between benchtop assays and multi-ton industrial output. Our proprietary engineering models address thermal degradation of thermolabile compounds, solvent recovery systems, and phase separation challenges across our state-of-the-art pilot facilities.
Eliminate costly supplier fragmentation. By consolidating cellular toxicology, animal pharmacodynamics, and phase clinical validation with final cGMP bulk manufacturing, partners cut overall time-to-market by 35% to 45% while maintaining unified audit trails.
Every study milestone is executed according to structured stage-gate protocols, delivering fully reproducible analytical dossiers and validated active substances.
Evaluating wild-crafted and agricultural biomass across micro-climatic origins and seasonal harvests. Liquid chromatography coupled to high-resolution mass spectrometry (LC-HRMS) maps total active metabolite density to identify the peak extraction window.
Developing robust, reproducible analytical testing protocols using validated HPTLC fingerprinting, HPLC assays, and GC residual solvent detection. Establishing full-spectrum pharmacopeial release criteria covering purity, moisture, and microbial limits.
Optimizing multi-stage unit operations: ultrasonic-assisted extraction, supercritical CO2 fluid extraction, resin adsorption columns, and membrane ultrafiltration. Preserving thermolabile molecules via specialized low-temperature vacuum drying.
In vitro biological pathway verification, membrane permeability tests, and high-throughput cellular screening. Advancing into GLP-compliant in vivo animal models to establish median lethal doses (LD50), sub-chronic toxicity, Ames genotoxicity, and safe margins.
Structuring human pharmacokinetic/pharmacodynamic (PK/PD) investigations, bioequivalence assessments, and double-blind placebo-controlled Phase II/III trials. Collecting definitive efficacy data acceptable for global regulatory authorities.
Commercial manufacturing across pharmaceutical delivery formats: enteric-coated hard capsules, softgel encapsulation, rapid-dissolution tablets, lyophilized powders, sterile oral liquids, and standardized free-flowing granules packaged for global distribution.
Bridging pharmacopeial specifications across North American, European, and Asian jurisdictions with complete data integrity and audit readiness.
Every active ingredient dossier is reconciled against the United States Pharmacopeia (USP), European Pharmacopoeia (Ph. Eur.), and Chinese Pharmacopoeia (ChP). We deliver validated test methodologies verifying botanical authenticity while excluding adulterants.
Zero-tolerance screening for heavy metals (Pb, As, Cd, Hg via ICP-MS), residual pesticide screens adhering strictly to EU 396/2005 regulations, multi-mycotoxin assays (Aflatoxins B/G, Ochratoxin A), and irradiation screening via thermoluminescence dosimetry.
Accelerating investigational new drug (IND) and new dietary ingredient (NDI) filings. We furnish customers with Module 3 Quality documentation, stability testing records under ICH Q1A(R2) conditions, and complete process validation batches.
Decades of R&D services supporting leading national research hospitals and listed pharmaceutical corporations:
Deploying cutting-edge algorithmic discovery and biotransformation pipelines to unlock next-generation botanical bioactives with increased therapeutic indices.
By training neural network models on thousands of legacy TCM clinical formulations and pharmacological datasets, we simulate active compound interactions against human receptor libraries prior to benchtop synthesis, shortening preclinical discovery timeframes by 60%.
Migrating legacy batch extraction reactors to continuous-flow microfluidic processing. This approach reduces carbon footprints, guarantees isothermal consistency, minimizes organic solvent requirements, and delivers extreme batch-to-batch chemical conformity.
Harnessing engineered enzymatic cascades to convert high-abundance precursors into ultra-rare, high-value ginsenosides, minor cannabinoids, and target saponins. This delivers pharmaceutical purity while conserving endangered botanical species.
Comprehensive responses to technical, regulatory, and production inquiries regarding ODM/CDMO partnerships.
Direct links to request analytical validation packages, study protocols, and pilot-scale quote estimations for your botanical medicine portfolio.
